Outcomes of concurrent radiotherapy and weekly paclitaxel/carboplatin therapy in cervical cancer: a retrospective study

Purpose of investigation: To determine if concurrent chemoradiotherapy (CCRT) with paclitaxel and carboplatin is effective, convenient, and tolerable for cervical cancer treatment. Materials and Methods: The authors retrospectively reviewed the medical records of 49 patients. Primary outcomes included progression-free survival (PFS) and overall survival (OS). The Cox proportional hazards model was adjusted for all prognostic factors in the multivariable analysis. Results: Over the median follow-up time of 32 months in a sample consisting of 87.8% (43/49) squamous cell carcinoma and 12.2% (6/49) adenocarcinoma, two-year PFS and OS rates were 67.2% and 80.9%, respectively. In univariate analyses, stage, histology, performance status, tumor size, and age were significant variables for OS; only histology was significant in the multivariable analysis. Acute toxicity grade 3 or 4 neutropenia (85.7%), diarrhea (32.7%), and late toxicity grade 3 or 4 (12.2%) were detected. Conclusions: For cervical cancer treatment, CCRT with paclitaxel/carboplatin is satisfactory.

Uterine cervical neoplasms; Chemoradiotherapy; Paclitaxel; Carboplatin; Survival.

[1] Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al.: “Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer”. Lancet, 1997, 350, 535.

[2] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L. 3rd, et al.: “Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma”. N. Engl. J. Med., 1999, 340, 1154.

[3] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al.: “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer”. N. Engl. J. Med., 1999, 340, 1137.

[4] Eifel P.J., Winter K., Morris M., Levenback C., Grigsby P.W., Cooper J., et al.: “Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01”. J. Clin. Oncol., 2004, 22, 872.

[5] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al.: “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer”. N. Engl. J. Med., 1999, 340, 1144.

[6] Jaakkola M., Rantanen V., Grénman S., Kulmala J., Grénman R.: “In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines”. Cancer., 1996, 77, 1940.

[7] Sangkittipaiboon S.: “Long-term outcomes of concurrent chemoradiotherapy with weekly carboplatin in locally-advanced carcinoma of the uterine cervix patients”. J. Med. Assoc. Thai., 2014, 97, 12.

[8] Katanyoo K., Tangjitgamol S., Chongthanakorn M., Tantivatana T., Manusirivithaya S., Rongsriyam K., Cholpaisal A.: “Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients”. Gynecol. Oncol., 2011, 123, 571

[9] Go R.S., Adjei A.A.: “Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin”. J. Clin. Oncol., 1999, 17, 409.

[10] Chen M.D., Paley P.J., Potish R.A., Twiggs L.B.: “Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer”. Gynecol. Oncol., 1997, 67, 131.

[11] Pignata S., Frezza P., Tramontana S., Perrone F., Tambaro R., Casella G., et al.: “Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of thecervix uteri”. Ann. Oncol., 2000, 11, 455. [12] Singh R.B., Chander S., Mohanti B.K., Pathy S., Kumar S., Bhatla N., et al.: “Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study”. Gynecol. Oncol., 2013,129, 124

[13] Torfs S., Cadron I., Amant F., Leunen K., Berteloot P., Vergote I.: “Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer”. Eur. J. Cancer., 2012, 48, 1332

[14] Higgins R., Bussey M., Naumann W., Hall J., Tait D., Haake M.: “Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer”. Am. J. Obstet. Gynecol., 2007, 197, 205.e1.

[15] Pritchard R.S., Anthony S.P.: “Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis”. Ann. Intern. Med., 1996, 125, 723.

[16] “Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group”. BMJ, 1995, 311, 899.

[17] Marino P., Preatoni A., Cantoni A.: “Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis”. Cancer, 1995, 76, 593.

[18] Herskovic A., Martz K., al-Sarraf M., Leichman L., Brindle J., Vaitkevicius V., et al.: “Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus”. N. Engl. J. Med., 1992, 326, 1593.

[19] al-Sarraf M., Martz K., Herskovic A., Leichman L., Brindle J.S., Vaitkevicius V.K., et al.: “Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study”. J. Clin. Oncol., 1997, 15, 277.

[20] Kurihara M., Sakamoto H., Ohta Y., Takami T., Takami M., Nakayama Y., et al.: “Patient compliance and the quality of life are well maintained in weekly paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women (in Japanese)”. Gan. To. Kagaku. Ryoho., 2001, 28, 55.